In Memory of Lou Guarracina

Last week, we lost a friend, colleague and source of perpetual inspiration in a tragic and untimely accident.  While he leaves behind friends and family who will miss and mourn him, the passing of HighRes’s founder and Chief Technology Officer Lou Guarracina is also a substantial loss for life science research more generally, where his […]

Large Molecule Research: Higher Targeting Efficiencies Still Leave Room for Automation

The rise of biopharmaceuticals has evolved research paradigms and continues to displace use of traditional small molecule therapies in the market. Biologics are forecast to account for more than half of the Top 100 selling drugs by 2022, up from roughly one-third in 2012. Driving these therapies to market has required significant investment in upfront […]

Machine Learning and Drug Discovery

Yesterday, Recursion Pharmaceuticals announced that the Food and Drug Administration had cleared their investigational new drug application for a Phase 1 clinical trial in the treatment of cerebral cavernous malformation (CCM). While this is certainly good news for treating this rare genetic disease, it is also an important milestone in the use of machine learning […]

How AI is Transforming Drug Discovery

Bringing a new pharmaceutical drug to market takes about 12 years and can reach into the billions in R&D expenditures, industry leaders are now seeking more efficient methods of approaching this process and AI is emerging as a potential solution. The interest in AI-driven solutions for early stage drug discovery is growing steadily among biopharma […]

AI and Drug Discovery

AI WILL EMPOWER DRUG DISCOVERY, BUT NOT THROUGH IN SILICA EXPERIMENTATION Artificial intelligence, or “AI” for short, has been the topic of sweeping news coverage of late. In the life sciences arena, much focus has been given to the use of AI to help the drug discovery process. Articles like “Big pharma turns to AI […]